Core Insights - Huamei Haolian has completed a multi-hundred million RMB Series D financing round, led by Yifeng Capital, Yahui Long, Ventech China, and Fengqiao Capital, with participation from Dongfang Guozi, Jinsha River Ventures, and Tongji Alumni Fund. The funds will be used for clinical advancement and commercialization of core products [2]. Company Overview - Huamei Haolian Medical Technology (Beijing) Co., Ltd. was established in 2017, headquartered in Suzhou with an operational center in Beijing. The company positions itself as an AI digital health service technology group, providing health management service solutions covering the entire lifecycle from pre-diagnosis to post-diagnosis for clients in insurance, banking, and enterprises [3]. - The company has branches in multiple cities including Shanghai, Guangzhou, Hainan, Yinchuan, Hangzhou, and Hefei, as well as in the United States, serving nearly 300 B-end clients and covering over 56 million end users [3]. Product and Technology - The main products include AI intelligent applications, a medical service network, and an AI product system. The company has developed algorithms for "precise medical treatment" and "traditional Chinese medicine consultation," which have been officially filed in the precision medical field [8]. - The company has established a service network covering 1,650 top-tier hospitals nationwide and links with 8 international medical systems and 3,000 international experts [8]. - Diverse health management products include "AI General Practitioner," "AI Precise Medical Treatment," "AI Health Report Interpretation," and community healthcare assistants aimed at grassroots medical institutions [8]. Financing History - The financing history of Huamei Haolian includes several rounds, with the latest being a Series D round raising hundreds of millions of RMB. Previous rounds include a C+ round in September 2025 and a C round in July 2024, with various venture capital firms participating [9]. Patent Information - The company holds several patents, including a digital-based smart elderly care monitoring system and a smart medical response method based on big data, all of which have been authorized [10].

Core Viewpoint - Huamei Haolian, a domestic AI digital health service technology group, has completed a multi-billion RMB Series D financing round, aiming to provide comprehensive health management solutions through a B2B2C and B2B model [2][3] Business Model - The business model of Huamei Haolian is based on B2B2C and B2B, where the B-end payers include insurance companies, banks, and enterprises, while the C-end consists of the customers or employees of these B-end payers [4] - Health management services provide core value to payers by helping insurance companies acquire customers and manage health proactively, thereby reducing payout risks; for banks, quality medical resources enhance financial product differentiation; and for enterprises, offering health management services boosts employee productivity and controls commercial insurance costs [5][6] Founder Background - The founder and CEO, Xu Bingyu, has a background in the health industry and has previously worked at Disney, Bank of America Merrill Lynch, and Charles River Associates, where she observed the business model of UnitedHealth Group [7][8] Market Adaptation - Xu aims to create a "Chinese version" of UnitedHealth, but faces challenges due to the differences in the healthcare landscape between China and the U.S., particularly the concentration of medical resources in top-tier hospitals [9] Strategic Partnerships - In the initial years, Huamei Haolian established trust with hospitals and standardized cooperation mechanisms, which allowed the company to leverage top-tier hospital resources to expand its payer base [11] Strategic Choices - The company has made two strategic choices: not to engage in the sale of drugs or insurance, focusing instead on being a health technology group that provides services and innovation; and to avoid entering the insurance underwriting field, maintaining a neutral position [12] AI Integration - Huamei Haolian has invested in AI research to enhance health management products, developing core algorithms for "precise medical treatment" and "traditional Chinese medicine consultation," and has launched AI applications such as "AI General Practitioner" and "AI Health Report Interpretation" [14][15] User Experience Improvement - The company aims to improve user experience by connecting fragmented healthcare services through AI, allowing patients to engage actively in their health management and receive personalized health advice [16][17] Resource Allocation - AI changes the logic of medical resource allocation by allowing users to consult AI before seeking in-person care, thus optimizing the use of limited medical resources [18][19] Product Matrix - Huamei Haolian has developed over 150 service modules, with nearly half driven by AI, allowing payers to customize solutions based on their clients' needs [25] Market Expansion - The company has established partnerships with over 1,000 medical institutions and aims to deepen its presence in the domestic market, with projections indicating the health management service market in China will grow from 1.2 trillion RMB in 2025 to 2.5 trillion RMB by 2030 [27]